Treatment of mothers with allopurinol to produce therapeutic blood levels in newborns

D. Boda, I. Németh, P. Kiss, H. Orvos

Research output: Contribution to journalArticle

28 Citations (Scopus)


Objectives: A number of experimental and clinical studies have shown that allopurinol, a xanthine oxidase inhibitor, can reduce hypoxic-ischemic reperfusion injury, but only by preventive or early treatment, which is rarely possible in clinical circumstances. The aim of the present study was to evaluate whether allopurinol administered to the mothers before the onset of labor in animal experiments, or after the onset of labor in human studies, would cross the placenta so as to establish a therapeutic level of allopurinol in newborns without affecting the process of delivery. Material and methods: In randomized investigations, brood sows were treated with allopurinol prior to farrowing. In human studies, mothers with full-term or preterm pregnancies received a single dose of allopurinol orally immediately after the onset of labor. Results: In both animals and humans, the process of delivery and the postnatal events in the newborns were similar in the treated and the control groups. The free placental transfer of allopurinol and its metabolite oxypurinol led to the attainment of therapeutic blood levels in the resulting newborn piglets and human infants. Conclusions: The placental transfer of allopurinol administered to parturient mothers may be effective in starting the early treatment of newborns with a high risk of hypoxic- reperfusion cerebral damage.

Original languageEnglish
Pages (from-to)130-134
Number of pages5
JournalPrenatal and Neonatal Medicine
Issue number2
Publication statusPublished - Jan 1 1999



  • Allopurinol
  • Hypoxic-reperfusion brain damage
  • Oxidative stress
  • Placental transfer
  • Xanthine oxidase

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this